Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Letrozole
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Aromatase Inhibitors
100%
Disease Progression
50%
Objective Response Rate
50%
Clinical Benefit Rate
50%
Treatment Failure
41%
Median Time
25%
Advanced Breast Cancer
25%
No Significant Difference
16%
Postmenopausal Women
8%
Multivariate Analysis
8%
Serum Samples
8%
Breast Cancer Patients
8%
Endocrine Therapy
8%
Hormonal Therapy
8%
Bayes
8%
Immuno
8%
Upper Normal Limit
8%
Breast Cancer Population
8%
Predictive Factors
8%
Efficacy Endpoint
8%
Time to Treatment Failure
8%
Risk of Progression
8%
Nursing and Health Professions
Tamoxifen
100%
Letrozole
100%
Aromatase Inhibitor
100%
Disease Exacerbation
85%
Treatment Failure
85%
Breast Cancer
42%
Hormonal Therapy
28%
Salicylate Sodium
28%
Multivariate Analysis
14%
Time to Treatment
14%
Immunoglobulin
14%
Medicine and Dentistry
Letrozole
100%
Aromatase Inhibitor
100%
Tamoxifen
100%
Disease Exacerbation
85%
Breast Cancer
42%
Hormone Therapy
28%
Salicylate Sodium
28%
Multivariate Analysis
14%
Arm
14%
Postmenopause
14%
Immunoglobulin
14%
Time to Treatment
14%
Predictive Factor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Tamoxifen
100%
Aromatase Inhibitor
100%
Letrozole
100%
Disease Exacerbation
85%
Breast Cancer
42%
Salicylate Sodium
28%
Immunoglobulin
14%
Hormone Cancer Therapy
14%
Endocrine Therapy
14%
Immunology and Microbiology
Postmenopause
100%
Arm
100%
Intravenous Immunoglobulin
100%
Aromatase
100%